We are live on ! Find out more
LAB icon

Standard BioTools

144 hedge funds and large institutions have $480M invested in Standard BioTools in 2024 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 39 increasing their positions, 35 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,045% more call options, than puts

Call options by funds: $1.26M | Put options by funds: $110K

11% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 35

3% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 34

1% less funds holding

Funds holding: 145144 (-1)

18.23% less ownership

Funds ownership: 91.46%73.23% (-18%)

33% less capital invested

Capital invested by funds: $719M → $480M (-$239M)

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

Holders
144
Holders Change
-1
Holders Change %
-0.69%
% of All Funds
2.08%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
35
Increased
39
Reduced
35
Closed
34
Calls
$1.26M
Puts
$110K
Net Calls
+$1.15M
Net Calls Change
-$1.96M
Name Holding Trade Value Shares
Change
Change in
Stake
Legal & General Group
51
Legal & General Group
United Kingdom
$438K +$133K +54,436 +28%
California State Teachers Retirement System (CalSTRS)
52
California State Teachers Retirement System (CalSTRS)
California
$436K +$125K +51,211 +26%
AQR Capital Management
53
AQR Capital Management
Connecticut
$431K +$440K +179,817 +284%
Jane Street
54
Jane Street
New York
$429K -$2.79M -1,141,543 -82%
DCM
55
Driehaus Capital Management
Illinois
$419K
BCPWM
56
Bradley & Co Private Wealth Management
Florida
$396K -$547K -223,938 -50%
Susquehanna International Group
57
Susquehanna International Group
Pennsylvania
$395K -$4.58M -1,872,100 -89%
UBS Group
58
UBS Group
Switzerland
$311K -$754K -308,408 -64%
T. Rowe Price Associates
59
T. Rowe Price Associates
Maryland
$293K +$235K +96,174 +140%
CF
60
Corebridge Financial
Texas
$289K +$397K +162,312 New
Invesco
61
Invesco
Georgia
$287K +$339K +138,647 +596%
Rockefeller Capital Management
62
Rockefeller Capital Management
New York
$284K +$2.17K +890 +0.6%
Commonwealth Equity Services
63
Commonwealth Equity Services
Massachusetts
$276K
ZDA
64
Zweig-DiMenna Associates
New York
$249K -$892K -365,000 -72%
BNP Paribas Financial Markets
65
BNP Paribas Financial Markets
France
$241K +$290K +118,477 +667%
Wells Fargo
66
Wells Fargo
California
$236K +$299K +122,324 +1,091%
Janus Henderson Group
67
Janus Henderson Group
United Kingdom
$232K +$146K +59,549 +83%
JP Morgan Chase
68
JP Morgan Chase
New York
$230K -$1.13M -462,893 -78%
Deutsche Bank
69
Deutsche Bank
Germany
$223K +$297K +121,593 +2,896%
New York State Common Retirement Fund
70
New York State Common Retirement Fund
New York
$216K +$299K +122,200 New
Manulife (Manufacturers Life Insurance)
71
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$208K +$287K +117,395 New
WC
72
Wexford Capital
Florida
$190K +$263K +107,619 New
VOYA Investment Management
73
VOYA Investment Management
Georgia
$182K +$252K +103,036 New
RC
74
RBF Capital
California
$178K -$834K -341,000 -77%
MS
75
Maven Securities
Jersey
$177K +$244K +100,000 New

LAB Hedge Fund Activity: Q2 2024 in Review

144 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2024, worth a combined $480M — down 33% from $719M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new LAB positions and 34 closed out — a net gain of 1 holder — while 39 added to existing stakes and 35 trimmed.

The largest buyer was BlackRock, adding an estimated $39.8M. The largest seller was Indaba Capital Management, exiting entirely with an estimated $20M sold.

  • 144 institutional investors held Standard BioTools (LAB) as of Q2 2024, down from 145 in Q1 2024.
  • Funds reported $480M of Standard BioTools stock for Q2 2024, down 33% quarter-over-quarter.
  • 35 funds opened new Standard BioTools positions in Q2 2024 and 34 closed out, a net change of +1 holder.
  • The largest Standard BioTools buyer in Q2 2024 was BlackRock, an estimated $39.8M added.
  • The largest Standard BioTools seller in Q2 2024 was Indaba Capital Management, an estimated $20M sold.

Based on aggregated 13F filings for Q2 2024.